Introduction
Sézary syndrome (SS) is defined as a peripheral T cell neoplasm with the clinical triad of erythroderma, leukemic expansion of neoplastic cells (Sézary cells) and generalized lymphadenopathy. 1 Circulating Sézary cells have a unique micromorphology, ie a nucleus with a cerebriform contour and a high nucleus-to-cytoplasm ratio. 1, 2 While the immunophenotype of Sézary cells is frequently indistinguishable from that of mature CD4 +
CD45RO
+ CD45RA − 'memory' T cells, 3 a high percentage of leukemic and skin-infiltrating Sézary cells lacks CD7 antigen expression. 4, 5 CD7 is physiologically expressed on the majority of human T and on NK cells as well as on cells in early stages of T, B and myeloid differentiation. 3 Immature T leukemia cells highly express CD7 whereas CD7 is generally absent on malignant mature T cells, including HTLV-1 + T leukemia and CD4 + Sézary leukemia cells. 3 Recent data revealed a predominance of leukemic cells of the CD7-negative subset during disease progression. 6 The mechanism of accumulation of Sézary cells in the skin is still a matter of discussion. In other leukemias and lymphomas, aberrant proliferation 7 or, alternatively or in addition, a defect in cell death accounts for the accumulation of malignant cells. 8 Because the proliferation index of Sézary cells is usually low, 9 it seems to be likely that a delay in apoptosis is predominant over aberrant proliferation in this disease. This is supported by the fact that bcl-2 is strongly expressed in CTCL (cutaneous T cell lymphoma), whereas Ki-67 expression is only found in advanced stages of the disease. 10, 11 Increased bcl-2 expression, however, seems to be a rare event since it was found in Sézary cells of three out of seven patients 11 and no aberrant bcl-2 expression was found by Garatti et al. 12 Accordingly, Fas (CD95) is reported to be not or in decreased levels expressed in peripheral blood T lymphocytes in patients with CTCL. 9, 11 This observation, however, is controversely discussed as Kamarashev et al 13 More recently, CD7 was shown to be a ligand of galectin-1 that initiates a signaling cascade resulting in apoptosis of CD7 + T cells. [18] [19] [20] [21] Considering the rather abundant presence of galectin-1 in human tissues, 22, 23 we assume that CD7-negative Sézary cells may be resistant to galectin-1-mediated cell death thereby favoring their accumulation within the tissues during progression of the disease. Using a panel of stimulation experiments we demonstrate here that CD7 − Sézary cells are resistant to galectin-1-induced cell death compared to neoplastic CD7 + T cells from patients with Sézary syndrome (SS) or non-SS leukemia. Independent of the potential mechanisms summarized above, resistance to galectin-1-mediated apoptosis may account for the accumulation of CD7-negative Sézary cells during progression of the disease.
Patients, materials and methods

Patients
Twelve patients with peripheral T cell leukemia diagnosed and treated at the Departments of Dermatology of the Saarland University Hospital and the Humboldt University Berlin were included in this study. Of them, eight patients had SS and four had non-SS leukemias with the histological subtypes T cell chronic lymphocytic leukemia (T-CLL, three patients) and T cell acute lymphoblastic leukemia (T-ALL, one patient), respectively, according to EORTC classification. 1 Fifty percent of the patients was male, and the median age was 51 years (range, 7-75 years).
The diagnosis of SS was established by a characteristic erythroderma, diagnostic skin biopsy specimens, and blood Sézary count of Ͼ1000/l. All Sézary patients were seronegative for antibodies against human T cell lymphocytic virus-I and did not receive any systemic therapy in the last 2 weeks. PCR analysis revealed a dominant TCR-␥ DNA rearrangement in both skin and blood of all eight patients tested indicating a clonal population of malignant cells. In patients 7 and 8, clonal T cells were detected in both CD7
− and CD7 + T cell subsets by PCR analysis of the TCR-␥ rearrangement. By twocolor immunofluorescence utilizing TCR-␤ and CD7-specific antibodies, respectively, we detected a TCR-␤ + CD7 − T cell clone in the peripheral blood of six out of eight Sézary patients tested. Patient information is summarized in Table 1 .
Cells and reagents
JURKAT is a T leukemia line (ATCC TIB 152), H9 is a derivative of the HUT-78 T cell line established from a patient with SS (ATCC HTB-176), MOLT-4 is a T leukemia line (ATCC CRL-1582), and SE-AX 24 is a CD7 + T cell line established from a patient with SS. Human dermal microvascular endothelial cells were obtained from CellSystems (St Katharinen, Germany) and cultured in endothelial cell growth medium (CellSystems). Normal CD4 +
CD7
+ and CD4 + CD7 − T cells were isolated from peripheral blood (buffy coats) as described. 25 Because CD7 expression decreases after magnetic separation and restored after 12 h of in vitro culture (unpublished observation), cells were washed twice for antibody removal and subsequently cultured overnight at 37°C. Galectin-1 was isolated from human placenta by ionexchange and affinity chromatography on divinyl-sulfone-activated lactose-sepharose 4B as described. 26, 27 Traces of immunoglobulin were removed by chromatography on protein A-sepharose 4B.
Death assays
PBMC were separated in CD7
− and CD7 + T cells by use of magnetic cell sorting (MACS) as described. 25 After restoration of antigen expression in positively selected T cells (CD7 + T cells) (RPMI 1640 medium, 10% FCS; 37°C, 5% CO 2 , overnight), CD7
− and CD7 + T cells (5 × 10 6 cells each) were stimulated with PHA (8 g/ml RPMI 1640 medium, 10% FCS) for 5 days. Because PHA triggers activation-induced cell death, apoptotic and necrotic T cells were removed after PHA stimulation by centrifugation in a Ficoll-Paque gradient. Viable cells (trypan blue negative) were seeded in 96 flat- Leukemia bottom wells (2 × 10 5 cells/well) in medium, in medium plus galectin-1 (4 g/ml, corresponding to 0.3 M), or in medium plus galectin-1 (4 g/ml) and ␤-lactose (100 mM), respectively, for 8 h. Stimulation for a longer time period and with higher PHA concentrations was found to lead to unspecific necrotic cell death. CD69 expression was used as a marker for cellular activation after PHA stimulation. In a second set of experiments, quiescent and PHA-activated T cells (2 × 10 5 cells/well), respectively, were cocultured for 8 h in 96 flatbottom wells with or without stimulated or non-stimulated human endothelial cells, respectively. Endothelial cells were prestimulated by incubation with IFN-␥ (15 ng/ml) for 18 h. To test for specificity, cells were additionally incubated with ␤-lactose (100 mM), a blocking ligand of galectin-1. After incubation for 8 h, T cells in the supernatants were carefully removed by washing the wells twice. The number of apoptotic cells was determined by annexin V-FITC/propidium iodide (AV/PI) staining and flow cytometric analysis utilizing an EPIXS XL (Beckman-Coulter, Krefeld, Germany) equipped with WinMDI software. Early apoptotic (AV+/PI−) plus late apoptotic (AV+/PI+) cells were recorded as apoptotic cells in this study.
For the study of Fas-induced apoptosis antibodies 7C11 and ZB4 (Immunotech, Krefeld, Germany) were used. Blocking of TNF-␣-mediated apoptosis in Sézary cells was performed with antibody MAb1 (Pharmingen, Heidelberg, Germany).
Results
Galectin-1 binds to the glycan residues of certain CD molecules including CD2, CD3, CD4, CD7, CD43 and CD45. 18, 20, 21, 23 We analyzed the expression of these CD molecules on peripheral blood mononuclear cells (PBMC) from healthy donors and from patients with SS and non-SS leukemia, respectively (Table 2) . PBMC from Sézary patients harbor a substantial number of CD7 − T cells (range 71-100%, average 86%); the number of CD4 +
CD7
+ and CD8 + CD7 + T cells was in the range of Ͻ2-27% (average 14%) dependent on the clinical stage of the disease. The cell surface glycoproteins CD45 and CD43, involved in the induction of apoptosis by galectin-1, 28 are homogeneously expressed on Sézary cells. T cells from patients with acute lymphatic leukemia (T-ALL) and chronic lymphatic leukemia (T-CLL), respectively, also express these marker molecules. Both CD4 +
+ and CD4 + CD7 − T cells from the peripheral blood of healthy controls (n = 10; one donor is representatively shown in Table 2 ) consistently express CD2, CD3, CD4, CD43 and CD45 at high levels SS, Sé zary syndrome; T-CLL, T cell chronic lymphocytic leukemia; T-ALL, T cell acute lymphoblastic leukemia. T cells from different healthy donors (n = 10; one representative donor is shown) and PBMC from patients with Sé zary syndrome (n = 8) and T cell leukemias (n = 4), respectively, were stained with monoclonal antibodies specific for CD7, CD2, CD3, CD4, and CD45 or with an isotype-matched control antibody. The following antibodies were used: MT910 (CD2), UCHT1 (CD3), MT310 (CD4), DK25 (CD8), DF-T1 (CD43), 4KB5 (CD45RA), UCHL-1 (CD45RO) (all from DAKO, Hamburg, Germany), clone FN50 mAb (CD69) (BD Pharmingen, Heidelberg, Germany), and 3A1 (CD7) from Sigma (Deisenhofen, Germany). T-ALL and T-CLL cells used in this study express a mature CD2
+ 'memory' helper T cell type in accordance with previous reports. 47, 48 Stained cells were subsequently analyzed by flow cytometry using an Epics XL (Coulter). Results are given as percent positive cells.
( Table 2 ). Whereas CD4 +
− T cells constitute the main population of PBMC from Sézary patients (73-100%), CD7-negative T cells in the blood of healthy donors are rare (Ͻ2%) and belong to post-thymic CD4 + cells. 25 Galectin-1 mediates apoptotic cell death via binding to CD7. 18 Whereas CD45 is not essential for galectin-1-mediated cell death, 18 the role of CD43 in galectin-1-induced apoptosis is not yet clear. 29 To determine the sensitivity towards galectin-1-mediated cell death, we monitored T cells from healthy donors and from patients with SS and other T cell leukemias, respectively, for apoptotic cell death upon incubation with galectin-1. Unstimulated CD4 
+ cells enter apoptosis whereas activated CD69 + cells of the CD4 + CD7 − subset do not (Figure 1b, c) . These data are in accordance with a previous report 18 demonstrating that CD7 mediates galectin-1-induced apoptosis in activated T cells from healthy donors. CD7 + cells from Sézary patients SS1, SS6, SS7 and SS8, respectively, prestimulated with PHA, entered apoptosis upon incubation with galectin-1 ( Figure 1b) . As control, CD7
+ SE-AX cells entered apoptosis upon galectin-1 incubation, the frequency of which was increased upon prestimulation of SE-AX cells with PHA. In contrast to T cells of the CD7
+ subset, cells of the CD7 − population from the peripheral blood of all SS patients tested were resistant to galectin-1-mediated apoptosis, even after prestimulation with PHA ( Figure 1c ). For comparison, unstimulated and PHA stimulated cells of the CD7 − T cell line H9 did not enter apoptosis upon galectin-1 incubation.
PHA-stimulated CD7 + T cells from patients with T-CLL and T-ALL, respectively, entered apoptosis in the presence of galectin-1 (Figure 1d ) with the exception of patient T-CLL2. The differential sensitivity of T leukemia cells may be due to deviations in glycosylation of CD7, in the capacity for cellular aggregation and/or in intracellular signal transmission. As controls and in accordance with recent reports, 18, 19 MOLT-4 cells are sensitive whereas JURKAT cells are resistant to galectin-1-mediated cell death.
Galectin-1-induced cell death of PHA-stimulated T cells is specific because it is prevented in the presence of ␤-lactose (100 mM) (Figure 1b-d) , a competitive inhibitor of galectin-1. 30 Incubation of unstimulated or stimulated T cells, respectively, with ␤-lactose did not alter cell survival in this assay making a direct effect of ␤-lactose upon the cells unlikely.
To test the reactivity of T cells towards cell-bound galectin-1, we used endothelial cells that physiologically express galectin-1 on the cell surface, [31] [32] [33] − and CD7 + T cells (2 × 10 5 cells), respectively, from patient SS6 were cultured in 96-round-bottom wells in the presence of galectin-1 (4 g/ml) for 8 h. Apoptotic cells were monitored by annexin V-FITC/propidium iodide (AV/PI) staining. Early apoptotic (AV+/PI−) and late apoptotic (AV+/PI+) cells were summarized as apoptotic cells throughout this study. AV-PI+ cells were considered as necrotic cells and gated out. (b, c, d) Quiescent and PHA-activated (8 g/ml) T cells were seeded in 96-round-bottom wells in medium (í) or in medium plus galectin-1 (4 g/ml) (`) or in medium plus galectin-1 (4 g/ml) and ␤-lactose (100 mM) (), respectively. The number of apoptotic cells was determined by AV/PI staining. (b) The number of CD7 + T cells from patients SS2, SS3, SS4 and SS5 was less than 7% of total PBMC (cf. Table 2 ), therefore no death assays were performed with CD7 + T cells from these patients. MOLT-4, SE-AX, JURKAT and H9 cells served as controls. Data represent the mean ± s.d. of at least three independent experiments. Statistical analysis was performed using the two-tailed Student's t test. *P Ͻ 0.001, as compared with medium. ND, not determined.
IFN-␥-stimulated endothelial cells increased the number of apoptotic CD4
+
CD7
+ cells even more compared to coculture with unstimulated endothelial cells (55.9 ± 2.3% vs 10.9 ± 2.3% apoptotic cells (mean ± s.d.)). Coculture of quiescent and PHA-prestimulated CD7 − T cells, respectively, with unstimulated endothelial cells revealed 12.9 ± 2.3% and 15.9 ± 2.3% apoptotic cells, respectively, compared to 13.9 ± 2.3% vs 15. 
Discussion
Sézary patients harbor substantially increased numbers of CD7 − T cells in the peripheral blood compared to healthy donors or patients with other leukemias. Galectin-1, a cellbound lectin ubiquitously expressed in solid tissues, is known to bind to CD7, CD43 and CD45. 28, 34 Whereas a substantial proportion of Sézary cells lacks CD7 expression, CD45 and CD43 are homogeneously expressed on CD7 + and CD7
− malignant cells as they are on T cells from healthy donors (cf. Table 2 ). The latter observations are in accordance with recent reports. [35] [36] [37] Whereas, to the best of our knowledge, CD43 expression on cells of Sézary lymphoma or Mycosis fungoides has so far not been analyzed, several reports indicate that essentially all T cells infiltrating primary cutaneous neoplasms 38 as well as cutaneous acute graft-versus-host disease and erythema multiforme 39 are positive for CD43. By incubation with purified galectin-1, we found that PHAactivated CD69 + CD7 + T cells from healthy donors are sensitive to galectin-1-mediated apoptosis that is specifically blocked by ␤-lactose. This is also observed for three out of four CD7 + leukemia cell specimens from patients with chronic and acute lymphatic leukemia, respectively. CD7
− Sézary cells as well as CD7 − T cells from healthy donors, in contrast to CD7 + T cells from the same donors, are resistant to galectin-1-mediated cell death. This is unlikely to be due to induction of cell proliferation because CD7 − Sézary cells require CD28 costimulation in addition to PHA stimulation (McCusker et al 40 and data not shown).
Our results demonstrating the involvement of CD7 in the induction of galectin-1-mediated cell death are of particular impact. In addition to CD7, CD43 and CD45 are ligands for galectin-1. Whereas both CD7
− and CD7 + T cells from healthy donors and patients with T cell leukemias homogeneously express CD45 and CD43 (Table 2) , only activated CD7 + T cells entered apoptosis upon binding to galectin-1. The death signal obviously enters via the CD7 cell and potentially is furthermore mediated by association of the CD43-CD7 complex with CD45 in order to induce tyrosine phosphorylation. 28, 29, 34 The mechanism of galectin-1-induced apoptosis, so far, seems to be distinct from that triggered by Fas or CD3 engagement. 19 In a recent publication, Rabinovich and coworkers 41 demonstrated that binding of galectin-1 to CD7 triggers activation of AP-1 and downregulates bcl-2 expression. This mechanism may counteract the recently reported IL-15-induced upregulation of bcl-2 expression in CD7 − Sézary cells. 15 Whereas CD7 − Sézary cells are resistant to galectin-1-mediated apoptosis, the cells are sensitive to TNF-␣ and Fasmediated apoptosis (Rappl, Abken and Reinhold, unpublished data) . This phenomenon may be due to, eg the differential expression of certain caspases or caspases inhibitory proteins like survivin 8, [42] [43] [44] or the dysregulation in the death receptor and mitochondrial signaling pathways 45 in Sézary cells. In concert with activation-induced cell death, galectin-1-mediated apoptosis of activated CD7 + T cells is likely to be involved in processes that resolve inflammation at the end of an immune response. Loss of CD7 expression and, subsequently, resistance to galectin-1-mediated apoptosis may reflect an immune escape mechanism as present in CD7
− Séz-ary cells. In contrast, CD7
+ Sézary cells, found in the peripheral blood of a significant number of patients with advanced diseases, 46 are sensitive to galectin-1-mediated cell death. The differential sensitivity to galectin-1-mediated cell death may contribute to the observed accumulation of CD7 − Sézary cells in skin and peripheral blood during progression of the disease. In this framework, the proportion of CD7
− cells within the CD4
+ T cell population of Sézary patients warrants attention for delineation of potential prognostic information.
